Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 11 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
113 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
IC PHARMA DISTRIBUTION from Brussel, company number BE0502266889, closed financial year 2025 with a result of € -460 after tax. For that financial year IC PHARMA DISTRIBUTION recorded a gross margin of € 1,198 and equity of € -346,912. Compared with financial year 2024, the result moved from € 33,542 to € -460. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.
€ -346,912
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -460
▼ still € 33,542 profit in 2024
Profit after tax over the fiscal year.
€ 10,627
▼ 20% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -498,312.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 42
▼ € 14,356 vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 370,023 | € 1,164 | € 34,014 | € 1,198 | ▼ 96% |
| Profit after taxes | € 344,696 | € -2,143 | € 33,542 | € -460 | ▼ € 34,002 |
| Equity | € -377,851 | € -379,994 | € -346,452 | € -346,912 | |
| Total debts | € 911,030 | € 763,458 | € 522,389 | € 391,547 | ▼ 25% |
| Cash | € 18,649 | € 13,680 | € 13,288 | € 10,627 | ▼ 20% |
| Retained profit | € -529,251 | € -531,394 | € -497,852 | € -498,312 | |
| Balance sheet total | € 533,179 | € 383,464 | € 175,937 | € 44,635 | ▼ 75% |
Key figures of IC PHARMA DISTRIBUTION, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IC PHARMA DISTRIBUTION?
What happened at IC PHARMA DISTRIBUTION in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 460 (▼ € 34,002 vs 2024). Source: NBB ↗
- INTERCONCEPT SRL became a director. NBB
- Tangie LE GALL became a director. NBB
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 344,696 profit in 2022 to € 460 loss in 2025.
Paid € 202 in corporate taxes since 2022.
Best year ever: 2022, with € 344,696 profit.
A new publication or filing at IC PHARMA DISTRIBUTION? We notify you, reason included.
Follow IC PHARMA DISTRIBUTIONDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of INTERCONCEPT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
IC PHARMA DISTRIBUTIONBehind IC PHARMA DISTRIBUTION are INTERCONCEPT SRL and Tangie LE GALL. The shares are held by INTERCONCEPT (83.3%). It owns 1% of BIO WINK SC itself.
Directors
According to the 2025 annual accounts
Director · represented by Jean-Baptiste VAN HAMME
Also active at: BENCH SYSTEM, IC PHARMA, Bio Wink, COSMEX
since 2019
since 2019
Shareholders
83.3%
Participations
1%
Establishments
Establishment units
Physical locations of this company
Congresstraat 35
1000 Brussel
Middelweg 90
1130 Brussel
Active since 2 October 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 113 companies are registered at this address.
All companies at this address →Caisse d'Entraide de Prêts et de Financements
€ 19,883 gross margin · 2024
Société pour la Production et le commerce de Dérivés organiques
ISS FACILITY SERVICES
€ 350.1 million revenue · 2025
NERM
€ 20,430 gross margin · 2025
ISS CATERING
€ 106.8 million revenue · 2025
+108 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0502.266.889
- VAT number
- BE 0502.266.889
- Registered office
- Congresstraat 35, 1000 Brussel
- Names & denominations
- IC PHARMA DISTRIBUTION
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 4 January 2013
- Peppol
- Not registered
- Activities · NACE
Overige activiteiten van uitgeverijen, met uitzondering van het uitgeven van software
Activiteiten van webportalen
Overige financiële dienstverlening, neg
Handel in eigen onroerend goed
Webportalen